<DOC>
	<DOCNO>NCT00893373</DOCNO>
	<brief_summary>Sorafenib multikinase inhibitor act various cellular pathway involve genesis acute myeloid leukemia ( AML ) . Sorafenib therefore promise candidate improvement chemotherapy result AML . This clinical trial evaluate efficacy sorafenib add standard chemotherapy AML patient 18 60 year age . Patients randomise receive either sorafenib capsule placebo addition chemotherapy . The placebo sorafenib group compare regard event-free survival clinical outcome . An event either treatment failure relapse death . According study hypothesis , sorafenib group less event placebo group .</brief_summary>
	<brief_title>Study Evaluating Sorafenib Added Standard Primary Therapy Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion criterion : Patients newly diagnose AML ( except APL ) accord FAB WHO classification , include AML evolve MDS hematologic disease AML previous cytotoxic therapy radiation ( secondary AML ) Bone marrow aspirate biopsy must contain ≥ 20 % blast nucleate cell differential blood count must contain ≥ 20 % blast . In AML FAB M6 ≥ 30 % nonerythroid cell bone marrow must leukemic blast . In AML define cytogenetic aberration , proportion blast may &lt; 20 % . Age ≥ 18 ≤ 60 year Informed consent , personally sign date participate study ECOG performance status 01 Life expectancy least 12 week Adequate liver renal function assess laboratory requirement conduct within 7 day prior Screening Exclusion criterion : Patients eligible standard chemotherapy per discretion treat physician Central nervous system manifestation AML Cardiac disease : heart failure NYHA III IV ; unstable coronary artery disease ( MI 6 month prior study entry permit ) ; serious cardiac ventricular arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Chronically impaired renal function ( creatinine clearance &lt; 30 ml/min ) ( CockcroftGault formula ) Patients undergoing renal dialysis Chronic pulmonary disease relevant hypoxia Known HIV and/or hepatitis C infection Evidence history severe nonleukemia associate bleed diathesis coagulopathy Evidence recent history CNS disease , include primary metastatic brain tumor , seizure disorder Resting blood pressure ( BP ) consistently high systolic 160 mmHg and/or diastolic 95 mmHg Any severe concomitant condition make undesirable patient participate study could jeopardize compliance protocol Patients major surgery , open biopsy significant traumatic injury within 4 week start first dose Serious , nonhealing wound , ulcer bone fracture Uncontrolled active infection &gt; Grade 2 NCICTC version 3.0 Concurrent malignancy AML History organ allograft Allergy study medication excipients study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>sorafenib</keyword>
</DOC>